NASDAQ: ANNXAnnexon Inc Stock
$2.49-0.22 (-8.12%)
Updated Jun 13, 2025
ANNX Price
$2.49
Fair Value Price
$0.15
Market Cap
$273.19M
52 Week Low
$1.29
52 Week High
$7.85
P/E
-2.11x
P/B
1.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$167.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$140M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ANNX Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANNX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANNX
Ranked#413 of 464
Ranked#413 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important ANNX news, forecast changes, insider trades & much more!
ANNX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANNX ($2.49) is overvalued by 1,566.84% relative to our estimate of its Fair Value price of $0.15 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANNX ($2.49) is not significantly undervalued (1,566.84%) relative to our estimate of its Fair Value price of $0.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANNX due diligence checks available for Premium users.
Valuation
ANNX fair value
Fair Value of ANNX stock based on Discounted Cash Flow (DCF)
Price
$2.49
Fair Value
$0.15
Overvalued by
1,566.84%
ANNX ($2.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANNX ($2.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.11x
Industry
-108.97x
Market
31.36x
ANNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
4.66x
ANNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANNX's financial health
Profit margin
Revenue
$0.0
Net Income
-$54.4M
Profit Margin
0%
ANNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$303.0M
Liabilities
$59.2M
Debt to equity
0.24
ANNX's short-term assets ($268.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANNX's short-term assets ($268.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$50.1M
Investing
$97.6M
Financing
$59.0k
ANNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANNX vs Biotech Stocks
Annexon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.